title: Impact of impaired aerobic capacity on liver transplant candidates.
abstract: BACKGROUND
  Oxygen consumption at peak exercise (peak VO2) is the most accurate index of aerobic capacity (AC), which reflects the physical condition of an individual and is currently considered the gold standard for cardiorespiratory fitness. Evaluation of peak VO2 to identify high-risk candidates for liver transplantation (LT) may represent an interesting approach. The aims of this study were (a) to describe AC and identify factors independently associated with peak VO2; (b) to analyze the prognostic value of peak VO2 in patients referred for preliminary evaluation of LT; and (c) to provide preliminary data on the influence of peak VO2 on length of hospitalization and the need for oxygen support after LT.
  
  
  RESULTS
  Peak VO2 was determined in patients referred for preliminary evaluation for LT. One hundred thirty-five candidates were included. More than half had severe alterations in peak VO2. Age, gender, model-for-end-stage liver disease (MELD) score, tobacco use, and hemoglobin were independently associated with peak VO2. Candidates with severe alterations in peak VO2 had a lower 1-year survival than others. Model-for-end-stage liver disease score and peak VO2 were independently associated with survival. In patients with a MELD above 17, those with severe alterations of peak VO2 AC had lower 1-year survival than the others. Among patients who underwent LT, those with severe impairment of peak VO2 showed a trend toward a higher mean length of hospitalization after LT and had significantly longer need for oxygen support.
  
  
  CONCLUSIONS
  Peak VO2 is severely impaired in candidates for LT and affects survival and post-LT course. Perioperative respiratory rehabilitation programs validated in lung and heart transplantation must be tested.
authors.affiliation: Service des Maladies de l'Appareil digestif et de la Nutrition, Hôpital Claude Huriez, France. s6@chru-lille.fr
authors.forename: Sébastien
authors.initials: S
authors.lastname: Dharancy
authors.forename: Malcolm
authors.initials: M
authors.lastname: Lemyze
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Boleslawski
authors.forename: Remy
authors.initials: R
authors.lastname: Neviere
authors.forename: Nicole
authors.initials: N
authors.lastname: Declerck
authors.forename: Valérie
authors.initials: V
authors.lastname: Canva
authors.forename: Benoit
authors.initials: B
authors.lastname: Wallaert
authors.forename: Philippe
authors.initials: P
authors.lastname: Mathurin
authors.forename: François R
authors.initials: FR
authors.lastname: Pruvot
mesh_terms: D002319:Cardiovascular System / Q000000981:diagnostic imaging / Q000503:physiopathology*; D005080:Exercise Test; D017079:Exercise Tolerance; D005260:Female; D006801:Humans; D007902:Length of Stay; D008103:Liver Cirrhosis / Q000401:mortality / Q000503:physiopathology* / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption; D010102:Oxygen Inhalation Therapy; D010865:Pilot Projects; D011446:Prospective Studies; D012129:Respiratory Function Tests; D012137:Respiratory System / Q000503:physiopathology*; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography